The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma

Abstract Background Osteosarcoma (OS) is a tumour with a high malignancy level and a poor prognosis. First-line chemotherapy for OS has not been improved for many decades. Bromodomain and extraterminal domain (BET) and histone deacetylases (HDACs) regulate histone acetylation in tandem, and BET and...

Full description

Bibliographic Details
Main Authors: Bo Yu, Lang Liu, Feng Cai, Yuanxiang Peng, Xiaofeng Tang, Duo Zeng, Teng Li, Feifei Zhang, Yiping Liang, Xuhui Yuan, Jiayu Li, Zhengzai Dai, Qi Liao, Xiao-Bin Lv
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Cancer Cell International
Subjects:
OTX015
WT-161
Osteosarcoma
Synergistic efficacy
β-Catenin
Online Access:https://doi.org/10.1186/s12935-022-02443-y

Internet

https://doi.org/10.1186/s12935-022-02443-y

Similar Items